Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD2 | P25440 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27159897 | 1.00 | MAP4K1 (0.39) | MAP4K1BRD4BRD2FLT3SYK | |
| SCHEMBL29914914 | 0.94 | MAP4K1 (0.39) | MAP4K1BRD4BRD2FLT3SYK | |
| SCHEMBL27160031 | 0.94 | MAP4K1 (0.39) | MAP4K1BRD4BRD2FLT3SYK | |
| SCHEMBL27159816 | 0.80 | MAP4K1 (0.40) | MAP4K1FLT3 | |
| SCHEMBL29914792 | 0.80 | MAP4K1 (0.40) | MAP4K1FLT3 | |
| SCHEMBL27160003 | 0.76 | FGFR1 (0.38) | FLT3 | |
| SCHEMBL27159964 | 0.74 | ALK (0.41) | SYK | |
| SCHEMBL29914840 | 0.74 | TGFBR1 (0.36) | — | |
| SCHEMBL27159607 | 0.73 | LMNA (0.38) | FLT3 | |
| SCHEMBL30816190 | 0.73 | BMPR1B (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425479-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-12-26 | — | — | US | disclosed |
| EP-4330246-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | Ontario Institute for Cancer Research (OICR) (CA) | 2024-03-06 | — | — | EP | disclosed |
| CN-117597336-A | Halogen substituted amino aza-heteroaryl compounds as inhibitors of hematopoietic progenitor kinase 1 (HPK 1) | 安大略省癌症研究所(OICR) | 2024-02-23 | — | — | CN | disclosed |
| WO-2022226665-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425479-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | DCK, CMPK1, WNK1 | MAP4K1 161/4885BRD4 1305/4885BRD2 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.